Login to Your Account

OXPHOS fixation: Series A lets Immunomet breathe, raising $5.2M for its pipeline

By Randy Osborne
Staff Writer

Tuesday, March 8, 2016

Immunomet Therapeutics Inc.’s chief scientific officer, Sanghee Yoo, told BioWorld Today that $5.2 million in series A money will take the company to the start of phase I trials with oxidative phosphorylation (OXPHOS) inhibitor IM156 and fund operations into 2017, though the firm has “not provided specific details” on an immuno-oncology program, also in the pipeline, he said.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription